Jan 30 2012
KineMed, Inc. (www.kinemed.com) today announced a non-exclusive research collaboration with Pfizer Inc. (NYSE:PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's Dynamic ProteomicsTM technology platform to map the impact of potential drug candidates on specific metabolic pathways.
“We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets”
Diabetes is an increasingly challenging global healthcare problem and in the United States affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations, and new cases of blindness among adults in the United States.
Despite over 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.
"We are delighted to be collaborating with Pfizer in taking novel and innovative approaches, by targeting disease pathways that have previously remained undeveloped as drug targets," said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. "We are using our translational platform to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials."
Antibiotic activity altered by interaction with nanoplastics, new research shows